Home - Valneva
WEBSep 12, 2024 · Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.
Valneva COVID-19 vaccine - Wikipedia
WEBValneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies. [6] [7] [8] In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do ...
The Valneva VLA2001 COVID-19 vaccine: What you need to know
WEBAug 18, 2022 · The Valneva vaccine is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has issued interim policy recommendations for the use of …
Valneva Reports Positive Phase 3 Results for Inactivated, …
WEBOct 18, 2021 · Saint Herblain (France), October 18, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive topline results from the Phase 3 pivotal trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva Provides Clinical and Regulatory Updates for its COVID …
WEBMar 2, 2023 · Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against the chikungunya virus and Lyme disease.
EMA recommends Valneva’s COVID-19 vaccine for authorisation …
WEBJun 23, 2022 · The European Commission will now fast-track the decision-making process to grant a decision on the standard marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva, allowing this vaccine to be included in vaccination programmes rolled out across the EU.
Valneva and Pfizer Report Further Positive Phase 2 Results, …
WEBSep 28, 2021 · Saint-Herblain (France) and New York (United States), September 28, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE), today announced further positive Phase 2 results, including booster response, for Lyme disease vaccine candidate VLA15.
What’s the Valneva COVID-19 vaccine, the French shot that’s …
WEBMay 7, 2021 · Valneva’s vaccine, called VLA2001, is based on tried and tested vaccine technology. It’s the technology used in the vaccine against poliovirus and in some types of flu vaccines.
Interim recommendations for use of the Valneva VLA2001 vaccine …
WEBAug 18, 2022 · These WHO interim recommendations for use of the Valneva VLA2001 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) on its 11 August 2022 extraordinary meeting and the evidence summary included in the background document and annexes referenced below.
Immunogenicity and safety of an inactivated whole-virus COVID …
WEBSep 5, 2022 · The Valneva COVID-19 vaccine (VLA2001; Valneva Austria, Vienna, Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine. We aimed to assess the safety and immunogenicity of primary vaccination with VLA2001 versus the ChAdOx1-S (Oxford-AstraZeneca) adenoviral-vectored vaccine.